10 May 2015

VISCHER advises CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, in its USD 89 m Series A and Series B financing, the largest Swiss financing for some time. The financings were led by strategic investors, SR One and Celgene Corporation, respectively, and included new investors New Enterprise Associates (NEA) and Abingworth, alongside the Company's founding investor, Versant Ventures. The VISCHER Team was led by Dr. Matthias Staehelin (Partner) with Marius Meier, Moritz Jäggy (all Corporate), and Nadia Tarolli (Tax).

Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk

You are currently offline. Some pages or content may fail to load.